All In Biotech

Drug Trial Radar · NCT07889492

A Study of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB06 Versus Placebo in Adults With Moderate to Severe Non-segmental Vitiligo

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Aug 5, 2026

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Edesa Biotech Inc.Industry
Sponsor type
Industry
Collaborators
JSS Medical Research Inc.
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of EB06 intravenous infusion (loading dose of 20mg/kg followed by a maintenance dose of 10mg/kg) compared with placebo in adults with moderate to severe non-segmental vitiligo.. Vitiligo is a chronic autoimmune skin disorder characterized by the loss of skin pigmentation due to the destruction of melanocytes. EB06 is a fully human monoclonal antibody that binds and neutralizes CXCL10, a chemokine implicated in the trafficking of anti-melanocytic T-cells to the epidermis and in inducing cell death. Elevated levels of CXCL10 have been associated with both the initiation of the disease and the maintenance of vitiligo lesions. The study will evaluate the safety, tolerability, and efficacy of EB06 in adults with moderate to severe non-segmental vitiligo.

Conditions

  • Non-Segmental Vitiligo (NSV)

Interventions

  • Placebo IVOther

    Placebo IV

  • EB06Biological

    EB06 IV loading 20 mg/kg followed by 10 mg/kg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean percent change from baseline in F-VASI at Week 28Time frame: 28 Weeks

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • Vida Clinical Research

    Edmonton, Alberta, Canada · Not yet recruiting

  • Guelph Dermatology Research

    Guelph, Ontario, Canada · Not yet recruiting

  • Clear Skin Dermatology

    Newmarket, Ontario, Canada · Not yet recruiting

  • FACET Dermatology

    Toronto, Ontario, Canada · Recruiting

  • CURAEX

    Panama City, Panama · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.